Table 3.
Neuropathy Rates According to Demographic, Clinical, and Treatment Characteristics
| Characteristic | Grades 2-4 Neuropathy | Grades 3-4 Neuropathy | ||||||
|---|---|---|---|---|---|---|---|---|
| No, No. (%) | Yes, No. (%) | OR (95% CI)* | P* | No, No. (%) | Yes, No. (%) | OR (95% CI)* | P* | |
| Total | 1,150 (82) | 251 (18) | 1,280 (91) | 121 (9) | ||||
| Mean age (years) | 72.5 | 73.0 | 1.04 (1.01 to 1.07) | .006 | 72.6 | 73.1 | 1.04 (1.00 to 1.08) | .03 |
| Age, categories (years) | ||||||||
| < 75 | 806 (82) | 172 (18) | Reference | 898 (92) | 80 (8) | Reference | ||
| ≥ 75 | 344 (81) | 79 (19) | 1.28 (0.94 to 1.75) | .12 | 382 (90) | 41 (10) | 1.46 (0.97 to 2.22) | .07 |
| Race | ||||||||
| Asian/Pacific Islander | 16 (73) | 6 (27) | 2.00 (0.75 to 5.29) | .16 | 17 (77) | 5 (23) | 3.63 (1.26 to 10.50) | .02 |
| Black | 112 (87) | 17 (13) | 0.84 (0.49 to 1.44) | .52 | 121 (94) | 8 (6) | 0.86 (0.41 to 1.84) | .70 |
| Native | 7 (100) | 0 | 7 (100) | 0 | ||||
| Unknown | 16 (80) | 4 (20) | 0.99 (0.32 to 3.07) | .99 | 18 (90) | 2 (10) | 1.16 (0.26 to 5.16) | .85 |
| White | 999 (82) | 224 (18) | Reference | 1,117 (91) | 106 (9) | Reference | ||
| Ethnicity | ||||||||
| Not Hispanic | 1,123 (82) | 248 (18) | Reference | 1,252 (91) | 119 (9) | Reference | ||
| Hispanic | 27 (90) | 3 (10) | 0.46 (0.13 to 1.61) | .23 | 28 (93) | 2 (7) | 0.61 (0.13 to 2.75) | .52 |
| Sex | ||||||||
| Female | 311 (80) | 77 (20) | Reference | 343 (88) | 45 (12) | Reference | ||
| Male | 839 (83) | 174 (17) | 1.06 (0.74 to 1.50) | .76 | 937 (92) | 76 (8) | 0.82 (0.52 to 1.29) | .39 |
| Time of initial registration | ||||||||
| < 2004 | 475 (81) | 113 (19) | Reference | 526 (89) | 62 (11) | Reference | ||
| 2004 or later | 675 (83) | 138 (17) | 0.97 (0.72 to 1.31) | .87 | 754 (93) | 59 (7) | 0.63 (0.42 to 0.94) | .02 |
| Kind of taxane | ||||||||
| Docetaxel | 704 (88) | 99 (12) | Reference | 761 (95) | 42 (5) | Reference | ||
| Paclitaxel | 446 (75) | 152 (25) | 2.20 (1.52 to 3.18) | < .001 | 519 (87) | 79 (13) | 2.86 (1.70 to 4.80) | < .001 |
| Cancer stage/high risk | ||||||||
| Low | 643 (82) | 138 (18) | Reference | 713 (91) | 68 (9) | Reference | ||
| High | 507 (82) | 113 (18) | 1.00 (0.75 to 1.33) | 1.00 | 567 (91) | 53 (9) | 0.89 (0.60 to 1.32) | .56 |
| Planned treatment time in protocol, days | ||||||||
| < 126 | 389 (83) | 82 (17) | Reference | 430 (91) | 41 (9) | Reference | ||
| ≥ 126 | 761 (82) | 169 (18) | 1.05 (0.71 to 1.55) | .79 | 850 (91) | 80 (9) | 1.34 (0.81 to 2.22) | .26 |
| Platinum treatment | ||||||||
| No | 793 (86) | 125 (14) | Reference | 855 (93) | 63 (7) | Reference | ||
| Yes | 357 (74) | 126 (26) | 1.68 (1.18 to 2.40) | .004 | 425 (88) | 58 (12) | 1.08 (0.67 to 1.74) | .77 |
*
Odds ratios and P values adjusted for age, race (black/white/other), sex, cancer stage/risk, date of initial enrollment, and planned treatment time according to the protocol (at or above v below the median), and stratified by treatment type (docetaxel v paclitaxel) and platinum treatment (yes/no).